Quick Answer
Acrivon Therapeutics, Inc. reported Total Assets of $129.72 million for fiscal year 2025.
Acrivon Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $129.72M | -34.0% |
| 2024 | $196.59M | +42.2% |
| 2023 | $138.26M | -23.7% |
| 2022 | $181.23M | +70.0% |
| 2021 | $106.59M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $145.30M | -32.3% | -8.4% |
| June 30, 2025 | $158.58M | -31.2% | -10.1% |
| March 31, 2025 | $176.35M | +46.3% | -10.3% |
| December 31, 2024 | $196.59M | +42.2% | -8.4% |
| September 30, 2024 | $214.68M | +42.1% | -6.9% |
| June 30, 2024 | $230.59M | +44.1% | +91.3% |
| March 31, 2024 | $120.52M | -29.2% | -12.8% |
| December 31, 2023 | $138.26M | -23.7% | -8.5% |
- Acrivon Therapeutics, Inc. showed a decrease of -34.0% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, Acrivon Therapeutics, Inc.’s total assets has grown by 21.7% (from $106.59 million to $129.72 million).
- The most recent figure is from Acrivon Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: